skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures

Original Research

(2352) Views  (571) Full article downloads

Authors: Jun Iwamoto, Atsushi Miyata, Yoshihiro Sato, et al

Published Date September 2009 Volume 2009:5 Pages 773 - 779
DOI: http://dx.doi.org/10.2147/TCRM.S6901

Jun Iwamoto1, Atsushi Miyata2, Yoshihiro Sato3, Tsuyoshi Takeda1, Hideo Matsumoto1

1Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Internal Medicine, Yahata Clinic, Tokyo, Japan; 3Department of Neurology, Mitate Hospital, Fukuoka, Japan

Abstract: A retrospective study was conducted to evaluate the outcome of treatment with alendronate (ALN) for 5 years in postmenopausal Japanese women with an increased risk of fractures. Forty postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures (mean age: 75.4 years) were analyzed; 33 patients were treated with alendronate and 7 were treated with alfacalcidol (ALF, controls) in an outpatient clinic run by general practitioners. The metacarpal bone mineral density (BMD) measured using a computed X-ray densitometer, urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of alkaline phosphatase (ALP) were monitored during the 5-year treatment period. The urinary NTX and serum ALP levels decreased significantly in the ALN group, compared with the ALF group. The metacarpal BMD was sustained in the ALN group but decreased significantly in the ALF group; the difference between these two groups was also significant. The present study evaluated the outcome of treatment with ALN for 5 years in postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures. ALN successfully suppressed bone turnover and sustained the metacarpal BMD over the 5-year period of treatment in postmenopausal Japanese women with an increased risk of fractures.

Keywords: alendronate, osteoporosis, osteopenia, risk factors for fractures, postmenopausal women






 

Other articles by Dr Jun Iwamoto



Readers of this article also read:

Substitution of anticonvulsant drugs
Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis
Parenteral clevidipine for the acute control of blood pressure in the critically ill patient: a review
Pegylated liposomal doxorubicin in ovarian cancer
Comparison of linear–stochastic and nonlinear–deterministic algorithms in the analysis of 15-minute clinical ECGs to predict risk of arrhythmic death
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
The role of urate and xanthine oxidase in vascular oxidative stress: future directions
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist